FDA Determines Regulatory Review Period for BAXDELA IV INJECTION Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of BAXDELA IV INJECTION, a new drug application (NDA) 208611, as required by law following the submission of patent extension applications to the US Patent and Trademark Office (USPTO).